RP1/Nivolumab Yields Promising Antitumor Activity in Non-Melanoma Skin Cancer
Source: Cancer Network, February 2022
Patients with non-melanoma skin cancer achieved promising antitumor activity following treatment with RP1 and nivolumab.
Treatment with RP1 and nivolumab (Opdivo) resulted in promising antitumor responses and a well-tolerated safety profile in a population of patients with non-melanoma skin cancer (NMSC), according to findings from the phase 2 IGNYTE trial (NCT03767348) that were presented at 2022 Multidisciplinary Head and Neck Cancers Symposium.
Patients with cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), Merkel cell carcinoma (MCC), and angiosarcoma achieved at least a partial response (PR) when receiving the combination therapy.READ THE ORIGINAL FULL ARTICLE